Abstract: A new pharmaceutically acceptable salt of hydroxysafflor yellow A as presented in formula (I), in particular new monomer compounds of potassium, ammonium, calcium, and magnesium salts of hydroxysafflor yellow A, preparation method therefor, and medical uses thereof are provided. Compared to hydroxysafflor yellow A, the hydroxysafflor yellow A pharmaceutical salts of the present invention have a purity of at least 98% and are monomer compounds that are safer, more effective, stable, and controllable. The salts have the effects against PAF- or ADP-induced platelet aggregation, and can be used in treating blood circulatory disorders such as platelet aggregation, coronary artery diseases, angina, and acute cerebral ischemia to the effect comparable to hydroxysafflor yellow A, wherein, n and M are defined as in the description.

Abstract: A hydroxysafflor yellow A sodium compound as shown in a formula (I) and preparation as well as medicinal application thereof are provided. According to the present invention, the safflower is utilized as a raw material. A monomer pharmaceutical compound, the hydroxysafflor yellow A sodium, is obtained by sufficient processes, and a purity thereof is surely above 98.5%. Therefore, the hydroxysafflor yellow A sodium is a monomer compound, which is safer, more effective, more stable and more controllable than hydroxysafflor yellow A, for treating blood circulation disorders such as platelet aggregation, coronary heart disease, angina pectoris and acute cerebral ischemia. Furthermore, the hydroxysafflor yellow A sodium has sufficient solubility and human tolerance.

Abstract: A new pharmaceutically acceptable salt of hydroxysafflor yellow A as presented in formula (I), in particular new monomer compounds of potassium, ammonium, calcium, and magnesium salts of hydroxysafflor yellow A, preparation method therefor, and medical uses thereof are provided. Compared to hydroxysafflor yellow A, the hydroxysafflor yellow A pharmaceutical salts of the present invention have a purity of at least 98% and are monomer compounds that are safer, more effective, stable, and controllable. The salts have the effects against PAF- or ADP-induced platelet aggregation, and can be used in treating blood circulatory disorders such as platelet aggregation, coronary artery diseases, angina, and acute cerebral ischemia to the effect comparable to hydroxysafflor yellow A, wherein, n and M are defined as in the description.

Abstract: A hydroxysafflor yellow A sodium compound as shown in a formula (I) and preparation as well as medicinal application thereof are provided. According to the present invention, the safflower is utilized as a raw material. A monomer pharmaceutical compound, the hydroxysafflor yellow A sodium, is obtained by sufficient processes, and a purity thereof is surely above 98.5%. Therefore, the hydroxysafflor yellow A sodium is a monomer compound, which is safer, more effective, more stable and more controllable than hydroxysafflor yellow A, for treating blood circulation disorders such as platelet aggregation, coronary heart disease, angina pectoris and acute cerebral ischemia. Furthermore, the hydroxysafflor yellow A sodium has sufficient solubility and human tolerance.

Abstract: A compound represented by Formula I, wherein M represents Na+, K+, NH4+, or Cs+; and 1) when Y represents SO42?: when m=1, then n=1; and when m=0.5, then n=1.5; and 2) when Y represents PO43?, when m=1, then n=2. The compound has good solubility and high bioavailability and can be formulated into oral pharmaceutical preparations and pharmaceutical preparations for injections.

Abstract: ?-lactamase resistant cephalosporin ester compound chosen from those represented by formula (I): wherein, and pharmaceutical salts thereof, composition thereof, and use thereof are disclosed.

Abstract: A compound represented by Formula I, wherein M represents Na+, K+, NH4+, or Cs+; and 1) when Y represents SO42?: when m=1, then n=1; and when m=0.5, then n=1.5; and 2) when Y represents PO42?, when m=1, then n=2. The compound has good solubility and high bioavailability and can be formulated into oral pharmaceutical preparations and pharmaceutical preparations for injections.

Abstract: ?-lactamase resistant cephalosporin ester compound chosen from those represented by formula (I): wherein, and pharmaceutical salts thereof, composition thereof, and use thereof are disclosed.

Abstract: An intermediate compound represented by formula (IV) as follows:

Abstract: The present invention discloses the ?-lactamase resistant cephalosporin ester compounds represented by the following formula (I), characterized in that the structures of the compounds are composed by connecting methyl ester residue of sulbactam halomethyl ester with carboxyl residue of semi-synthetic cephalosporins or salts of thereof. The present invention also provides the pharmaceutical salts of thereof, and the use of thereof in preparation of oral antibiotics.